Abbey Jenkins, Gamida Cell CEO
March 27, 2023 11:21 AM EDTUpdated 12:31 PM
People
R&D

Gami­da Cell makes more staff cuts and re­struc­tures as it fo­cus­es on po­ten­tial drug launch

Tyler Patchen

News Reporter

Gami­da Cell is mak­ing some re­struc­tur­ing moves as it pre­pares for the po­ten­tial ap­proval of its lead drug.

In Gami­da Cell’s 2022 year-end

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times